IHC for ATRX was available for 13 of the oligodendroglioma cases and all showed preservation of ATRX while only 3 cases (including the one for which IHC was not available) had Foundation Medicine results, none of which showed mutations in ATRX. This evidence concerns the gene ATRX and oligodendroglioma.